Inicio › Cáncer de seno › Nueva York › Rochester
Ensayos clínicos de Cáncer de seno en Rochester, NY
15 estudios para Cáncer de seno buscan participantes en centros de Rochester y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
ReclutandoFase 2
- University of Rochester Medical Center, Rochester
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Reclutando
- University of Rochester (URMC), Rochester
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
ReclutandoFase 2
- Wilmot Cancer Institute, Rochester
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
ReclutandoFase 3
- Rochester General Hospital Lipson Cancer Institute, Rochester
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
ReclutandoFase 3
- University of Rochester Medical, Rochester
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
ReclutandoFase 1
- Wilmot Cancer Institute, Rochester
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
ReclutandoFase 2
- University of Rochester Medical Center, Rochester
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
ReclutandoFase 3
- Pluta Cancer Center, Rochester
- University of Rochester, Rochester
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
ReclutandoFase 1
- University of Rochester - Wilmot Cancer Institute, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
ReclutandoFase 2
- University of Rochester Wilmot Cancer Institute, Rochester
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
ReclutandoFase 3
- Wilmot Cancer Institute Radiation Oncology at Greece, Rochester
- Highland Hospital, Rochester
- Pluta Cancer Center, Rochester
- y 3 más
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Reclutando
- University of Rochester, Rochester
Access to Genetic Testing in Underserved Patients With Cancer
ReclutandoSe aceptan voluntarios sanos
- University of Rochester, Rochester
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
ReclutandoFase 2
- University of Rochester, Rochester
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
ReclutandoEstudio observacional
- University of Rochester - Pluta Cancer Center, Rochester
Más información sobre Cáncer de seno en MedlinePlus
Ensayos de Cáncer de seno en otras ciudades
- New York City, NY136 estudios
- Houston, TX126 estudios
- Boston, MA112 estudios
- Nashville, TN81 estudios
- Los Angeles, CA73 estudios
- Edison, NJ68 estudios
- St. Louis, MO64 estudios
- Queens, NY64 estudios
- Durham, NC64 estudios
- Chicago, IL59 estudios
- Philadelphia, PA56 estudios
- Dallas, TX55 estudios
Otros estudios en Rochester
- Leucemia mielógena aguda16 estudios
- Cáncer de pulmón15 estudios
- Cáncer (todos los tipos)14 estudios
- Obesidad14 estudios
- Sobrepeso13 estudios
- Cáncer de pulmón de células no pequeñas13 estudios
- Cáncer de próstata10 estudios
- Cáncer metastásico8 estudios
- Mieloma múltiple8 estudios
- Cáncer de vejiga7 estudios
- Distrofia miotónica7 estudios
- Cáncer de páncreas7 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.